Market Overview - The U.S. job openings fell to the lowest level in over a year, indicating a cooling labor market[11] - The ADP report showed moderate growth in private sector employment for December, with labor demand remaining weak[11] - The S&P 500 index's expected price-to-earnings ratio is currently around 22 times, down from 23 times in November but still above the five-year average of 19 times[12] U.S. Stock Market Performance - On Wednesday, the S&P 500 index closed down, primarily due to weakness in financial stocks like JPMorgan and Blackstone[2] - The Nasdaq index saw a slight increase, driven by gains in Nvidia and Alphabet[2] - Major tech stocks mostly rose, with Google A up 2.43% and Microsoft up 1.04%, while Tesla and Apple saw declines of 0.36% and 0.77%, respectively[11] Hong Kong Stock Market Performance - The Hang Seng Index closed at 26,459, down 0.94% for the day, but up 3.23% year-to-date[3] - Technology stocks faced significant declines, with Alibaba down over 3% and Kuaishou down over 2%[9] - The automotive sector also struggled, with NIO dropping over 3% and several other manufacturers down more than 2% due to tightening subsidies and a forecasted 7% decline in China's auto market sales for 2026[9] Sector-Specific Insights - Oil stocks collectively fell, with Kunlun Energy and CNOOC down over 3% amid concerns over increased supply from Venezuela[9] - Pharmaceutical stocks performed well, particularly CRO and CDMO-related companies, with notable gains for clients like Kelaiying and Tigermed, rising 8.92% and 8.88% respectively[9] - The paper industry saw gains, with Nine Dragons Paper up 8.97% due to supply cuts and price increases announced by major companies[9]

Market Overview - The Shanghai Composite Index achieved a 14-day consecutive rise, closing at 4085.77, up 0.05% [1][2] - The Shenzhen Component Index rose 0.06% to 14030.56, while the ChiNext Index increased by 0.31% to 3329.69 [2] - The total market turnover reached 2.88 trillion, with the Shanghai and Shenzhen markets accounting for 2.85 trillion, an increase of nearly 50 billion compared to the previous trading day [2] Semiconductor Industry - The semiconductor sector saw significant activity, particularly in photolithography and memory chip stocks, with companies like Nanda Optoelectronics and Xinyuan Microelectronics hitting the daily limit of 20% increase [14] - Notable stocks included Xinyuan Microelectronics at 190.79, up 20%, and other companies like Anji Technology and Puran Shares also showing strong gains [15][14] - Analysts highlighted that the memory sector is in its early cycle, driven by advancements in AI models, increasing the demand for memory in chips, devices, and data centers [17] Coal Sector - The coal sector experienced a substantial rally, with stocks like Dayou Energy and Shaanxi Black Cat reaching their daily limit of 10% increase [18][19] - Futures for coking coal and coke both hit the daily limit, reflecting strong market demand [20] - Analysts noted that the average temperature in central and eastern China is expected to drop, which may enhance coal consumption, supporting prices in the near term [20] Hong Kong Market - The Hang Seng Index fell by 0.94% to 26458.95, with the Hang Seng Tech Index down 1.49% [6][7] - Technology stocks, including Tencent Music and Alibaba, saw declines of over 3%, while pharmaceutical and chip stocks performed well [7][10] Biotech Sector - The biotech sector in Hong Kong showed strong performance, with the Hang Seng Biotech Index rising over 4%, and companies like Rongchang Biotech and China Antibody seeing increases of over 10% [10][11]

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 | 代码 名称 | | 12月复权单位 累计单位 | | | --- | --- | --- | --- | | | 净值增长率8 净值元 | | | | 513060. SH 博时恒生医疗保健(QDII-ETF) | -10.17 | 0.59 | 63.02 2021-03-18 万琼 | 来源：同花顺 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@s ...

(责任编辑：华青剑) 来源：同花顺 中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，广发中证香港创新药 (QDII-ETF)单月下跌11.16%。截至2025年三季度末规模为138.75亿元。 2025年三季度前十大重仓股为信达生物、百济神州、药明生物、康方生物、中国生物制药、石药集 团、三生制药、药明康德、翰森制药、科伦博泰生物。基金经理刘杰现任广发基金管理有限公司指数投 资部总经理助理、基金经理。 | 代码 名称 | 12月复权单位 累计单位 规模亿元 基金成立日 基金经理 | | --- | --- | | | 净值增长率8 净值元 | | 513120. SH 广发中证香港创新药(QDII-ETF) | -11.16 1.20 234.03 2022-07-01 刘杰 | ...

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 来源：同花顺 (责任编辑：康博) 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 | 代码 名称 | 12月复权单位 累计单位 规模亿元 基金成立日 基金经理 | | --- | --- | | | 净值增长率8 净值元 | | 513060.SH 博时恒生医疗保健(QDII-ETF) | -10.17 0.59 63.02 2021-03-18 万琼 | ...

Group 1 - China's foreign exchange reserves reached a ten-year high of $3.3579 trillion, increasing by $11.5 billion from the previous month, while gold reserves rose for the 14th consecutive month to 74.15 million ounces, up by 30,000 ounces [1] - The State Administration for Market Regulation and the National Internet Information Office jointly issued regulations targeting issues in live-streaming e-commerce, including false marketing and counterfeit goods [1] - The Ministry of Industry and Information Technology and eight other departments released an action plan for "Artificial Intelligence + Manufacturing," aiming for significant advancements in AI technology and industry scale by 2027 [1] Group 2 - The People's Bank of China announced a 3-month reverse repurchase operation of 1.1 trillion yuan, marking the third consecutive month of equal-scale operations [2] - The A-share market saw a slight increase, with the Shanghai Composite Index rising 0.05% to 4085.77 points, achieving a record 14 consecutive days of gains [2] - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling 0.94% to 26,458.95 points, while tech stocks mostly retreated [2] Group 3 - Goldman Sachs projected a 20% increase in the MSCI China Index and a 12% increase in the CSI 300 Index by 2026, maintaining an overweight rating on A-shares and H-shares [3] - BlackRock increased its holdings in several Hong Kong stocks, including Haier Smart Home and WuXi Biologics, as of January 2, 2026 [3] - Ping An Life has increased its stake in Agricultural Bank of China H-shares to 20%, triggering a fourth stake increase [3] Group 4 - In December 2025, China's retail sales of passenger cars reached 2.296 million units, a year-on-year decrease of 13% but a month-on-month increase of 3% [7] - The logistics industry in China reported a business activity index of 52.4% in December 2025, reflecting sustained demand in the real economy [6] - The Ministry of Industry and Information Technology announced plans to upgrade industrial networks for over 50,000 enterprises by 2028 [6] Group 5 - The domestic commodity futures market closed mostly higher, with base metals leading the gains, and nickel reaching its daily limit [15] - The main contract for U.S. crude oil fell by 1.28% to $56.40 per barrel, amid concerns over increased supply from Venezuela [16] - The global memory market is entering a "super bull market," with prices expected to rise by 40%-50% in Q4 2025 [8]

Group 1 - The core viewpoint of the news highlights significant achievements in the innovation drug sector, with a record 76 innovative drugs expected to be approved for market in China by 2025, marking a historical high [1] - The healthcare payment system is continuously optimized, with the introduction of a "commercial insurance innovative drug directory" mechanism, which enhances the payment capacity for innovative drugs through the complementary combination of medical insurance and commercial insurance [1] - Institutions are optimistic about the pharmaceutical and biotechnology industry, with Donghai Securities predicting that China will officially enter a new era of innovative drugs by 2026 [1] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks including WuXi Biologics, Innovent Biologics, BeiGene, and others, accounting for over 71.80% of the total weight [2] - The management and custody fees for the Harvest Hong Kong Stock Connect Innovative Drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term allocation tool and professional investors for flexible trading needs [2]

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

Group 1 - Goldman Sachs projects a 20% increase in the MSCI China Index and a 12% increase in the CSI 300 Index by 2026, maintaining an overweight rating on A-shares and H-shares [1] - The report highlights a potential 14% growth in profits for Chinese listed companies in 2026, significantly better than the single-digit growth expected in 2025, driven by the rise of artificial intelligence and international expansion of listed companies [1] - The favorable risk-reward ratio for the Chinese stock market is indicated by low to mid-single-digit earnings growth rates, moderate valuations, and generally low levels of investor holdings [1] Group 2 - Internet and hardware companies are expected to achieve approximately 20% annual profit growth in 2026 due to the monetization of AI and advancements in AI-related capital expenditures [3] - The automotive sector's profits are predicted to double from low levels in 2025, with expected price-to-earnings ratios of 12.4 times for the next 12 months and 14.5 times for the CSI 300 Index, approaching reasonable valuation levels of around 13 times and 15 times [3] - Southbound capital inflows are anticipated to reach $200 billion, surpassing the record $180 billion net inflow in 2025, with domestic asset reallocation potentially bringing an additional 3 trillion RMB to the Hong Kong stock market [3]

行业多项关键政策突破与落地，首版《商业健康保险创新药品目录》于2025年12月正式发布，其构建 的"基本医保保基本，商保保创新"的多层次支付体系，为高值创新药开辟出市场新通路。 展望2026年，业内人士普遍看好，在产业政策对真创新、高水平创新的支持下，大量创新药BD将密集 落地。 商保实施与集采优化双轮推动下，创新药产业链高景气度有望延续，高价值创新药有望迎来第二增长曲 线。 港股创新药板块企业包括： 智通财经APP获悉，记者从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临 床用药迫切需求，国家药监局进一步优化这类药品审评审批。国家药监局表示，坚持以临床价值为导 向，鼓励申请人在中国开展全球同步研发、同步申报上市;鼓励临床急需境外已上市的原研药及仿制药 在境内申报，对于符合要求的可纳入优先审评审批范围。 公告显示，国家药监局将优化审评机制，加快审评速度;同时，也将完善检验制度，体现品种特点。 2025年我国已批准上市的创新药达76个，大幅超过2024年全年48个，创历史新高。此外，2025年我国创 新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，同样创历史新高。 据了解 ...